1. Fig. 7 BMS reduces the elevated expression of type I IFN–regulated genes both ex vivo in blood from patients with lupus and in a phase 1 study of normal healthy volunteers challenged with IFNα2A.
BMS reduces the elevated expression of type I IFN–regulated genes both ex vivo in blood from patients with lupus and in a phase 1 study of normal healthy volunteers challenged with IFNα2A. (A) Type I IFN–dependent gene expression in whole blood from patients with lupus was measured after incubation with either BMS (500 nM) or anti-IFNAR antibody (135 μg/ml) for 5 hours. Results are normalized to untreated blood for each patient, and the data represent means ± SD (n = 31); #P < by pairwise nonparametric comparison. (B) On day 13 of a multiple ascending dose study in healthy volunteers, 2 hours after the morning dose of BMS , IFNα2A was administered by subcutaneous injection to stimulate expression of IFN-responsive genes. Blood was collected at various times over the following 24 hours, and the expression of CXCL10, ISG20, and IFI27 was measured by quantitative PCR. The induction was normalized to samples from the same individual collected before challenge with IFNα2A, and the results represent geometric means ± SEM. The x axis denotes time after challenge with IFNα2A.
James R. Burke et al., Sci Transl Med 2019;11:eaaw1736
Copyright © 2019 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works